NCT04723706View on ClinicalTrials.gov

Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients

CompletedOBSERVATIONAL
Enrollment

33

Participants

Timeline

Start Date

March 19, 2021

Primary Completion Date

December 2, 2023

Study Completion Date

January 2, 2024

Conditions
Hematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)
Interventions
DIAGNOSTIC_TEST

COVID-19 serology IgG

patients with SCT or CART who decide to get their vaccines we will measure response by therapy by measuring COVID-19 serology IgG at the following schedule: Baseline +5 days after vaccination; 1 month +/- 10 days (after the first dose), 2 months +/- 10 days (after the 2nd dose), 3 months +/- 10 days, 6 months +/- 10 days and 12 months +/- 10 days

Trial Locations (1)

48202

Henry Ford Health System, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT04723706 - Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients | Biotech Hunter | Biotech Hunter